Pfizer (PFE) Q3 2026 Earnings Call: Q&A Summary

Q: How is the trispecific tilrekimig positioned in atopic dermatitis, and what are the timelines for other indications?

A: Alexandre de Germay stated that the Phase III program for atopic dermatitis is underway, including a head-to-head study against dupilumab. Phase II/III studies for COPD and Phase III studies for severe asthma are ongoing, with readouts expected in 2028 and 2029.

Q: What are the expectations for the upcoming Phase I/IIa amylin and combo data, and what is the titration schedule?

A: Management noted that the Phase IIb SOLIS study is fully recruited, with an efficacy readout expected in the second half of 2027. The Phase I/IIa study update is expected at the end of this year, focusing on safety and pharmacokinetics.

Q: Can you elaborate on the commercial positioning of the trispecifics?

A: Management explained that they are building capabilities in the U.S. and internationally to capture both naive and lapsed patients, noting that the large category allows for different patient profiles to be addressed.

Q: What were the U.S. net price dynamics in the third quarter, and what is the outlook for the near term?

A: CFO Cecile Guegan stated there were no material changes in gross-to-net dynamics during the third quarter, with performance driven by volume and market execution. Future guidance will reflect 2027 dynamics such as IRA, 340B, and MFN impacts.

Q: How should investors view the operating expense levels heading into the dividend integrity and Padcev transition?

A: Cecile Guegan confirmed the company is on track to deliver $7.2 billion in savings. She noted that while R&D investment is increasing, SG&A is expected to decline versus last year, and a second phase of cost savings totaling $2.5 billion will help mitigate margin erosion during the LOE transition.

Q: Is there an update on the STAT6 biomarker analysis and the decision to move to stage 2?

A: Chris Boshoff stated the program was adapted to incorporate additional drug-drug interaction studies, with a readout expected this year.

Q: What drove the decision to reduce the amylin and GLP-1 combo trial size?

A: Chris Boshoff clarified that the study was adapted for additional pharmacokinetic studies and there were no material changes to the trial.

Q: How does the new PIK3CA inhibitor fit into the broader breast cancer strategy?

A: Chris Boshoff explained that the internally discovered PIK3CA inhibitor is being tested in combination with atirmociclib, offering an advantage due to a lack of drug-drug interactions.

Q: What is the reaction to the AstraZeneca Volga data regarding Padcev cycles in bladder cancer?

A: Chris Boshoff noted the data reinforces the use of Padcev in muscle-invasive bladder cancer and increases confidence in ongoing trials, including the 309 study and the planned Phase III trial of Padcev plus tivunatamig.

Q: How are marginal dollars being invested between internal R&D, business development, and buybacks?

A: Cecile Guegan reiterated that priorities remain unchanged: investing in the business, maintaining the dividend, and preserving a strong balance sheet, with share repurchases becoming a lever post-LOE.

Q: Are there changes to MEVPRO-2 and -3 timelines following the MEVPRO-1 pushout?

A: Chris Boshoff stated MEVPRO-1 is expected to read out in Q1 2027, while MEVPRO-2 is expected in Q4 2027.

Q: Why is Pfizer not prioritizing another large deal, and is the pipeline better now than in the past?

A: Cecile Guegan stated the focus is on bolt-on acquisitions that complement the four existing therapeutic areas, noting that the pipeline has been significantly strengthened.

Q: What are the risks regarding MFN or scrutiny on OUS agreements in 2027?

A: Albert Bourla stated he expects a split government and does not anticipate legislative changes to MFN, noting that existing agreements provide stability.

Q: What are the thoughts on expanding berobenatide into inflammation, neuroscience, or oncology?

A: Chris Boshoff noted the goal is to establish berobenatide as a best-in-class monthly GLP-1 for obesity, with expansion into knee osteoarthritis and obstructive sleep apnea underway.

Q: How are the obesity and diabetes markets playing out in China, and what does this mean for berobenatide OUS?

A: Alexandre de Germay stated the company is satisfied with the progress, noting that the type 2 diabetes approval opened hospital and e-commerce channels, which is key to market penetration.

Q: What is the regulatory path forward for the Lyme vaccine?

A: Chris Boshoff stated the EMA has validated the marketing authorization application with an opinion expected in 2027, and discussions with the FDA are ongoing.

Q: Can you comment on the MEVPRO formulation change and the potential for neutralizing antibodies in the trispecific tilrekimig?

A: Management stated the MEVPRO study was adapted for a more tolerable dose with food, and regarding tilrekimig, no functional neutralizing antibodies have been observed to date.

Q: What are the high-level drivers for 2027, and why is there a disconnect between Street forecasts and internal growth expectations?

A: Cecile Guegan noted that 2027 drivers include LOE impacts, the ramp-up of the acquired portfolio, and cost initiatives. Albert Bourla added that discrepancies exist because the Street does not fully model the pipeline or the performance of new products like Nurtec and Elrexfio.